ICYMI: FDA Evaluating Packaging Changes to Immediate-Release Opioid Analgesics
The FDA announced last month that it is evaluating the public health and safety impact of modifying the Opioid Analgesic Risk Evaluation and Mitigation Strategy (OA REMS) to have fixed-quantity blister-packaging. This would be for opioid analgesics used in treating acute pain. As a recap, the Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act (SUPPORT Act) or HR 6, was a bipartisan bill passed in October of 2018. It
